Steno2Tech Study Shows CGM Improves Time in Range and A1C for Individuals with T2D

A recent study¹ was undertaken to evaluate long-term effects of continuous glucose monitoring (CGM) versus capillary blood glucose monitoring (CBG) in adults living with insulin-treated type 2 diabetes (T2D) currently not achieving targets. 

The study followed 76 participants who were split into two groups, using either CBG or CGM over the course of 12 months. Those who used a Dexcom CGM System showed notable improvement in glucose control and other health parameters, including reduced A1C, improvements in time in range (TIR), and decreased total daily dose (TDD) of insulin.

In addition, study participants using Dexcom CGM reported greater satisfaction in areas of treatment, glucose monitoring, general and diabetes-related health, and health behaviour.

<Download the PDF summary>

CGM Improves Health Outcomes in Individuals With T2D

The data demonstrated significantly improved outcomes in those who used CGM compared to those using CBG, including:

• Time in range increased by 15.2%
• Time above range decreased by 15.5%
• Insulin use decreased by 10.6 units TDD 

Other beneficial outcomes associated with use of CGM included a reduction in body weight of 3.3 kg with associated lower BMI of -1.1kg/m².

Benefits of Choosing Dexcom CGM for Insulin-Treated T2D

This most recent research adds to a growing body of clinical evidence demonstrating the effectiveness of Dexcom CGM in improving glycemic and metabolic outcomes.

This study found that CGM-correlated improvements were sustained over the long term, noting the benefits at six months were sustained at 12-months.

As well, researchers noted that CGM overcomes the limitations of traditional blood glucose monitoring–which can be painful, inconvenient, and fail to capture a complete glycemic picture, given the intermittent nature of CBG. In contrast, real-time CGM systems like Dexcom G7 provide glucose readings and trend arrows up to every 5 minutes, capturing crucial, actionable data 24 hours a day.

The study’s encouraging results provide compelling reasons to consider continuous glucose monitoring, like Dexcom G7, over a blood glucose monitoring device in those living with insulin-treated type 2 diabetes (T2D) currently not achieving targets.

As a healthcare provider, you can take action by proactively talking to adults living with insulin-treated T2D about using Dexcom CGM to help manage their diabetes. You can also request Dexcom G7 samples here.